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N europathic pain is a chronic form of pain that is characterized by spontaneous onset,  allodynia,  
and hyperalgesia.  Chronic pain can persist for months 
at a time and can be very difficult to manage or treat 
effectively.  Although various drugs,  such as anti-de-
pressants,  anti-convulsants,  and opioids,  have been 
used for analgesic effect,  they either have insufficient 
potency or produce adverse reactions.  The develop-
ment of novel drugs for neuropathic pain with fewer 
side effects and adequate efficacy has therefore been a 
focus of expectation.  To achieve this goal,  a great 
quantity of research has been conducted and various 
candidate compounds have been identified.  Thousands 
of compounds have been shown to be effective in pre-
clinical trials,  but only a limited number have been 
tested in humans.  The first obstacle to progressing from 
cell and animal to human studies is safety.  Even if a 
candidate compound could overcome this issue,  
patients would in the end have to bear the great cost 
burden of the time and resources required to prove the 
safety of the form synthesized for human trials.  One 
strategy to avoid this obstacle is the adaptation of exist-
ing approved drugs or compounds,  such as the above- 
mentioned anti-depressants and anti-convulsants,  
which were originally developed for other diseases.  
Known as “drug re-positioning,” this approach is now 
receiving attention.
Flavonoids are a group of plant metabolites consist-
ing of up to 6,000 different compounds which are 
responsible for the vivid colors of plants [1].  Quercetin,  
a flavonoid widely found in fruits and vegetables (e.g.,  
onions,  cranberries,  apples),  is known to have anti-ox-
idant,  anti-inflammatory,  and anti-nociceptive effects,  
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Quercetin is a flavonoid widely found in plants and marketed to the public as a supplement.  Several studies 
have reported its effect on glial cells.  This study aimed to examine the effect of quercetin on the development of 
neuropathic pain and the underlying mechanism in a spared nerve injury (SNI) rat model.  Male Sprague-
Dawley rats randomly assigned to the control or the quercetin group were subjected to SNI of the sciatic nerve.  
We measured pain behaviors on the hind paw and glial fibrillary acidic protein (GFAP) in the dorsal root gan-
glion (DRG) and spinal cord.  Oral administration of 1% quercetin,  begun before surgery,  attenuated mechan-
ical allodynia compared to the control group at days 7 and 10 after SNI.  On the other hand,  established pain 
was not attenuated in a post-dose group in which quercetin was begun 7 days after SNI.  Quercetin inhibited 
GFAP in the satellite glial cells of the ipsilateral L5 DRG on day 7 compared to the control group.  Quercetin 
suppressed the development of neuropathic pain through a mechanism partly involving the inhibition of satel-
lite glial cells.  As its safety is well established,  quercetin has great potential for clinical use in pain treatment.
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and is marketed to the public as a supplement for the 
alternative treatment of allergies,  asthma,  arthritis,  
gout,  hypertension,  and neurodegenerative disorders.  
However,  there is a lack of data to provide a scientific 
basis for the relevant treatment claims.  Epidemiological 
studies have demonstrated significant inverse correla-
tion between intake of flavonoids and cardiovascular 
disease.  Recently,  several studies have reported that 
quercetin reduces blood pressure in hypertensive ani-
mals and humans [2].  Quercetin has also been found to 
suppress inflammatory pain [3] and diabetic neuro-
pathic pain [4].  However,  the mechanisms involved in 
these effects have not been fully elucidated.
For many decades,  most research on neuropathic 
pain focused on neuronal mechanisms.  However,  
recent studies have demonstrated that glial cells also act 
as powerful modulators of pain [5] and indicate that 
they may be an attractive target for the treatment of 
chronic pain.  Accordingly,  several drugs that inhibit 
glial cells have been examined for their analgesic effect 
[6].  Quercetin is also reported to have effects on astro-
cytes [7],  but the detailed mechanism is not clear.  The 
aim of the present study was thus to examine the effect 
of quercetin on the development of neuropathic pain 
and to clarify the underlying mechanism.
Materials and Methods
Animals and drug treatment. All animal proce-
dures were carried out in accordance with the Ethical 
Guidelines for the Investigation of Experimental Pain in 
Conscious Animals issued by the International Associa-
tion for the Study of Pain [8].  The Board of Animal 
Care and Use Committee of Okayama University 
Medical School approved the study on July 30, 2014 
(OKU-2014410).
In total,  61 male Sprague-Dawley rats (CLEA Japan 
Inc.,  Tokyo,  Japan) weighing 150-240 g at the time of 
surgery were used in the study.  The animals were 
housed in cages under a 12-12 h light-dark cycle with 
free access to food and water.  A standard rodent diet 
(MF diet; Oriental Yeast Co.,  Tokyo,  Japan) with or 
without quercetin (Carbosynth,  Berkshire,  UK) was 
prepared by the manufacturer and daily diet consump-
tion was recorded.  Rats were randomly assigned to the 
different experimental groups.  The experimental rats 
were allowed to acclimatize to the facility for 5 days 
prior to surgery.
Surgical procedures. All the rats were placed 
under anesthesia with pentobarbital sodium (40 mg/kg 
intraperitoneally).  Additional inhalation anesthesia 
with isoflurane was given as needed.  Spared nerve 
injury (SNI) of the sciatic nerve [9] was performed as 
described previously with modification.  Briefly,  the left 
tibial nerve was exposed at mid-thigh level,  ligated with 
6-0 silk thread,  and cut,  while the common peroneal 
and sural nerves remained intact.  After appropriate 
hemostasis was confirmed,  the wound was closed.  All 
procedures were performed under aseptic conditions.
Behavioral assessment. Pain behavior was assessed 
by the von Frey test before and at 1 , 3 , 7 , 10 , 14,  and 21 
days after surgery.  Mechanical allodynia was measured 
via the hind paw withdrawal threshold (PWT) with von 
Frey filaments (Touch-Test Sensory Evaluator; North 
Coast Medical,  Morgan Hill,  CA,  USA).  The rats were 
placed individually in a plastic cage (13 × 10 × 15 cm3) 
with an elevated wire mesh bottom (openings 5×5 mm2),  
allowing full access to the plantar surfaces of both hind 
paws.  Mechanical stimuli were applied to the lateral 
plantar aspect of each hind paw with one of a series of 
nine von Frey filaments (0.4 , 0.6 , 1.0 , 1.4 , 2.0 , 4.0 , 6.0 ,  
8.0,  and 15.0 g).  Each trial was started with a von Frey 
force of 2 g for 1-2 sec.  The stimuli were given at inter-
vals of at least several seconds,  allowing for apparent 
resolution of any behavioral responses to previous stim-
uli.  On the basis of the response pattern and the force of 
the final filament,  the 50% PWT was determined by the 
up-down method of Dixon [10] and calculated using the 
formula described by Chaplan et al.  [11].  If the stron-
gest filament did not elicit a response,  the PWT was 
recorded as 15.0 g.
Cell culture. The C6 rat glioma cell line was 
obtained from American Type Culture Collection 
(Manassas,  VA,  USA; catalogue no.  CCL-107).  The 
cells were thawed and maintained in Dulbecco’s modi-
fied Eagle’s medium (Gibco,  Grand Island,  NY,  USA) 
supplemented with 10% fetal bovine serum (Gibco),  
100 U/mL penicillin,  and 100 mg/mL streptomycin 
(Wako,  Osaka,  Japan),  in an incubator containing 5% 
CO2 at 37°C.  Quercetin dissolved in dimethyl sulfoxide 
(DMSO) was added at final concentrations of 0 (vehi-
cle),  1 , 10 , 30,  and 50 μM in equalized volumes.  After 
1 h,  cells were stimulated with 1 ng/ml of recombinant 
rat interleukin-6 (IL-6; R&D Systems,  Minneapolis,  
MN,  USA) for 3 h and 10 h to measure phospho- signal 
transducer and activator of transcription 3 (STAT3) and 
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glial fibrillary acidic protein (GFAP),  respectively.
Western blotting. For in vivo study,  rats were 
anesthetized deeply with pentobarbital and perfused 
transcardially with 50 ml of saline 7 and 14 days after 
SNI.  The bilateral L5 dorsal root ganglions (DRGs) and 
spinal cords were excised and processed for western 
blotting.  For in vitro study,  cells were harvested with cell 
lysis buffer after IL-6 stimulation for 3 and 10 h.  Total 
protein concentrations were measured with a BCA pro-
tein assay kit (Pierce,  Rockford,  IL,  USA).  The pro-
teins were denatured and reduced by boiling in SDS and 
β-mercaptoethanol-containing buffers.  They were then 
electrophoresed and separated on gradient polyacryl-
amide gels (Any kD precast gel; Bio-Rad,  Hercules,  
CA,  USA) and transferred onto nitrocellulose mem-
branes.  The membranes were first labeled with anti-
GFAP antibody (1 : 5000,  #2389; Cell Signaling Tech-
nology,  Beverly,  MA,  USA),  anti-phospho-STAT3 
antibody (1 : 2000,  #9145; Cell Signaling Technology),  
and anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) antibody (1 : 100000,  #G8795; Sigma 
Aldrich,  St. Louis,  MO,  USA) as a loading control for 
2 h at room temperature.  After washing,  horseradish 
peroxidase-conjugated donkey anti-rabbit (1 : 5000,  
NA934; GE Healthcare UK,  Buckinghamshire,  UK) 
and donkey anti-mouse IgM (1 : 3000,  #sc-2064; Santa 
Cruz Biotechnology,  Santa Cruz,  CA,  USA) antibodies 
were added.  The membranes were then imaged using 
the enhanced chemiluminescence procedure (Bio-Rad).  
Densitometry was performed using Image Lab (Bio-
Rad),  and protein levels were expressed as values rela-
tive to the controls.
Immunohistochemistry. The rats were anesthe-
tized deeply with pentobarbital and perfused transcar-
dially with 50 ml of saline followed by 500 ml of 4% 
formalin 14 days after SNI.  The bilateral L5 DRGs were 
excised and post-fixed in the same fixative for 2 h and 
incubated in phosphate-buffered 30% sucrose over-
night.  These tissues were embedded in OCT com-
pound (Sakura Finetek,  Tokyo,  Japan) and 16 µm- 
thick frozen sections were cut and incubated overnight 
at 4°C with rabbit anti-GFAP antibody (1 : 1000,  
#12389; Cell Signaling Technology),  followed by incu-
bation with horseradish peroxidase-conjugated goat 
anti-rabbit IgG (1 : 200) and AlexaFluor 488-labeled 
tyramide (1 : 200) according to the manufacturer’s 
instructions (Life Technologies,  Eugene,  OR,  USA).  
Nuclei were visualized with DAPI (ProLong Gold 
Antifade Mountant with DAPI; Life Technologies).
Images were captured with a fluorescent microscope 
(EVOS FL Cell Imaging System; Life Technologies,  
Carlsbad,  CA,  USA) equipped with 20 × objective 
(numerical aperture = 0.45).
Statistical analysis. Behavioral changes and 
GFAP level were assessed as primary and secondary 
experimental outcomes,  respectively.  Data are expressed 
as the mean ± standard error of the mean (SEM).  For 
behavioral assessment data,  statistical analysis was per-
formed with two-way measurement analysis of variance 
(ANOVA) followed by Bonferroni’s post-hoc test.  
Differences were considered statistically significant at a 
p-value of < 0.05.  For western blotting analysis data,  
statistical significance was determined with one-way 
ANOVA followed by Bonferroni’s post-hoc test.  For 
food intake data,  statistical analysis was performed with 
Student’s t test.  A p-value of < 0.05 was considered sig-
nificant.
Results
Behavioral assessments. First,  we tested the pro-
phylactic effect of quercetin on the development of 
neuropathic pain.  In the quercetin pre-dose groups,  
rats were given MF diet containing 1% or 0.1% querce-
tin from 4 days before surgery until sacrifice.  The aver-
age intake of the diet is shown in Table 1.  The average 
intake of quercetin was 229 ± 13.0 (standard deviation) 
mg/day in the 1% quercetin group.  In the control 
group,  rats were given normal MF diet,  in which the 
quercetin content was under the limit of detection.  At 
baseline,  there was no significant difference in mechan-
ical withdrawal thresholds across the groups (Fig.1A,B).  
After SNI,  all rats developed ipsilateral tactile allodynia 
(Fig. 1A),  while the contralateral PWT did not vary 
significantly from baseline values (Fig. 1B).  In the 1% 
quercetin pre-dose group,  mechanical allodynia was 
attenuated compared to the control group with signifi-
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 (g/rat/day) 19.9±0.3 22.9±0.6 ＜0.01
Quercetin intake
(mg/kg/day) - 808±21
cant differences at days 7 , 14,  and 21 after SNI 
(9.57 ± 1.37 vs. 4.22 ± 0.86,  8.60 ± 1.24 vs. 3.38 ± 1.09 
and 8.73 ± 1.99 vs. 1.15 ± 0.37,  respectively).  On the 
other hand,  no effect was observed in the 0.1% querce-
tin pre-dose group.
Next,  we tested the reversal effect of a 1% quercetin 
diet.  In this experiment,  MF diet containing 1% quer-
cetin was started from 7 days after SNI (1% quercetin 
post-dose group).  In contrast to the pre-dose group,  
mechanical allodynia was not attenuated in this group 
(Fig. 2).  No motor deficiency was observed in any rat 
during the whole experimental period.
Effect of quercetin on GFAP. Many reports have 
demonstrated the anti-inflammatory effects of querce-
tin.  In the present study,  to identify the effect of quer-
cetin on glial cells in vitro and to account for the correla-
tion between quercetin administration and suppression 
of pain behavior,  we measured the GFAP level in a C6 
rat glioma cell line as a cellular astrocyte model.  
Although C6 cells constitutively expressed GFAP as well 
as primary cultured astrocytes,  the level was so faint 
that we employed IL-6 to enhance GFAP expression,  
since IL-6 is a key activator of GFAP in astrocytes via 
the STAT3 pathway [12] and has been reported to play 
important roles in various pathological pain states.  An 
inhibitory effect of quercetin on STAT3 activation was 
also reported previously [13].
The western blot analysis demonstrated that IL-6 
increased the levels of GFAP and phospho-STAT3 
(Fig. 3A).  These changes were suppressed by quercetin 
dose-dependently.  GFAP induction was decreased with 
30 µM of quercetin and was completely inhibited at 
50 µM of quercetin (Fig. 3A , B).
GFAP localization in DRGs. Satellite glial cells 
(SGCs) are glial cells in the peripheral nervous system 
that surround the individual neurons in the DRG.  They 
are thought to play a role similar to astrocytes in the 
central nervous system and are suggested to be involved 
in the development of pathological pain [14 , 15].  The 
use of GFAP as an astrocyte marker in the spinal dorsal 
horn has been well documented in many pain studies.  















Fig. 2 Diﬀerence in quercetin eﬀect on SNI-induced pain behavior 
(comparison of the timing of medication).  Time course of ipsilateral 
50% paw withdrawal threshold (PWT) in response to mechanical 
stimuli after SNI in the control group (white box,  n＝6) and 1% 
quercetin post-dose group (black box,  n＝9).  Statistical analysis 
was performed with two-way measurement ANOVA.  Data are 
































Fig. 1 Eﬀect of quercetin on SNI-induced pain behavior.  Time 
course of ipsilateral (A) and contralateral (B) 50% paw withdrawal 
threshold (PWT) in response to mechanical stimuli after SNI in the 
control group (white box,  n＝6-17),  1% quercetin group (black box,  
n＝9-20) and 0.1% quercetin group (gray box,  n＝6).  Statistical 
analysis was performed with two-way measurement ANOVA fol-
lowed by Bonferroniʼs post-hoc test.  Data are expressed as the 
means ± SEM.  ＊p＜0.05,  ＊＊p＜0.01 versus the control group.
In the present experiments,  immunohistochemistry 
was performed to localize GFAP in the DRG.  GFAP was 
expressed predominantly in the SGCs of the ipsilateral 
L5 DRG in the rats with SNI (Fig . 4).  No immunoreac-
tivity was seen in the neuronal somata.  GFAP immu-
noreactivities in the contralateral DRGs of both groups 
and in the ipsilateral DRGs of quercetin-treated rats 
were so faint that we performed western blot analysis to 
quantitate them.
Suppression of GFAP in DRGs and spinal cord by 
quercetin treatment. Previous reports have demon-
strated morphological changes in GFAP-immuno-
reactive cells and upregulation of GFAP content in the 
DRG after peripheral nerve injury [15 , 16].  We tested 
whether quercetin treatment suppressed the induction 
of GFAP caused by SNI.  Using western blot analysis,  
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Fig. 4 Photomicrographs of the immunohistochem-
ical localization of GFAP in DRGs.  (A) Bright-ﬁeld 
photograph of DRGs.  Green (B) and blue (C) immu-
noreactivities show GFAP and nuclei,  respectively.  
Nuclei surrounding neuronal cell bodies are those of 
SGCs.  (D) Merged image of DRGs.
Fig. 3 Inhibition of GFAP synthesis by 
quercetin in C6 glioma cells.  (A) Western 
blotting of whole cell lysates.  Cells were 
treated with quercetin at the indicated con-
centrations 1h before interleukin-6 (IL-6) 
stimulation and harvested 3h (pSTAT3) 
and 10 h (GFAP) after stimulation.  (B) 
Densitometry of GFAP.  Values are 
expressed as the GFAP densities relative to 
GAPDH as a loading control (n＝3).  Data 
are expressed as the means ± SEM.
we measured GFAP content in the L5 DRGs and spinal 
cords of the SNI model with and without quercetin 
treatment.  In the control group,  GFAP was signifi-
cantly induced in the ipsilateral L5 DRGs compared to 
the contralateral tissues on day 7 (Fig. 5A),  with dimin-
ished induction on day 14 (Fig. 5B),  as in a previous 
report [16].  In the quercetin group,  rats were given MF 
diet containing 1% quercetin from 4 days before the 
surgery until sacrifice.  In the L5 DRGs,  GFAP expres-
sion on the ipsilateral side was significantly inhibited by 
quercetin treatment on day 7 compared to the control 
group.  GFAP expression on the contralateral side did 
not vary between the control and quercetin groups.  We 
also performed western blotting on the L5 spinal cords.  
In both groups,  there were no differences between the 
ipsilateral and contralateral tissues on days 7 (Fig. 6A) 
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Fig. 5 Western blot analysis of GFAP protein expression in L5 DRGs with and without quercetin treatment.  (A) Western blotting and sta-
tistical analysis of densitometry 7 days after SNI.  ＊p＜0.05,  ＊＊p＜0.01.  (B) Western blotting and statistical analysis of densitometry 14 
days after SNI.  GFAP protein expression was normalized by GAPDH as a loading control.  Statistical analysis was performed with one-way 









































Fig. 6 Western blot analysis of GFAP protein expression in the L5 spinal cord with and without quercetin treatment.  (A) Western blot 
bands and statistical analysis of densitometry 7 days after SNI.  ＊p＜0.05,  ＊＊p＜0.01.  (B) Western blot bands and statistical analysis of 
densitometry 14 days after SNI.  GFAP protein expression was normalized by GAPDH as a loading control.  Statistical analysis was per-
formed with one-way ANOVA and Bonferroniʼs post-hoc test.  Data are expressed as the means ± SEM.
and 14 (Fig. 6B).  GFAP expression was significantly 
inhibited on both sides by quercetin treatment com-
pared to the control group on day 7.  This tendency was 
not observed at 14 days after SNI in the L5 spinal cords.
Discussion
Quercetin has been reported to have a number of 
clinical actions [2 , 17-20],  and its effects on pain have 
also been tested in different animal models [3 , 4 , 21].  A 
series of reports has focused on its effect on neuro-
pathic pain,  with a number of possible mechanisms 
suggested [22 , 23].  In the present study,  we demon-
strated the analgesic effect of quercetin using a rat SNI 
model.  Our results showed that oral administration of 
quercetin prevented the development of the mechanical 
allodynia caused by nerve injury,  whereas established 
neuropathic pain was not reversed.  The preventive 
effect was correlated with GFAP inhibition in the L5 
DRGs.  These results indicate the importance of SGCs in 
the development of neuropathic pain.
Quercetin has been reported to have a number of 
favorable properties,  including antioxidant,  antinoci-
ceptive,  and anti-inflammatory effects.  The analgesic 
action of quercetin has been demonstrated in several 
previous studies.  Quercetin inhibited nociceptive 
responses in capsaicin-,  glutamate-,  and formalin-in-
duced pain models in mice [21].  The authors suggested 
that these effects occurred via the modulation of 
GABAA,  GABAB,  and 5-HT receptors,  as well as the 
endogenous release of glucocorticoids.  Anjaneyulu et 
al.  reported that quercetin attenuates diabetic neuro-
pathic pain in mice through modulation of the opioid 
mechanism [4].
One of the effects of quercetin is inhibition of GFAP 
expression in injured astrocytes [7].  GFAP is an inter-
mediate filament protein that is expressed especially in 
astrocytes and is used as a marker of reactive glial cells 
[24].  GFAP is also found in SGCs,  which are promi-
nent glial cells in the DRG [25],  and GFAP upregula-
tion in SGCs after nerve injury has been reported [26-
28].  Finally,  it has been reported that spinal astrocytes 
are activated and play roles in various pain models [29].  
In our present experiments,  we observed increased 
GFAP levels in the bilateral spinal cords on day 7;  
however,  because there was no laterality,  which was 
observed in the behavioral assessments,  we focused on 
SGC as a target of quercetin.  The spinal GFAP activa-
tion was not seen on day 14.  We considered that this 
finding was due to a return of the GFAP level to base-
line,  although in previous studies the time-course of 
spinal GFAP has varied depending on the pain models,  
ages,  and species employed [30-32].
In addition to glial cells in the central nervous sys-
tem,  which are well known to be implicated in the 
induction and maintenance of neuropathic pain [29 , 33] 
SGCs in the sensory ganglia also contribute to neuro-
pathic pain [15].  Following peripheral nerve injury,  
SGCs undergo changes in cell number,  structure,  and 
function [34].  Axotomy increases the gap junction and 
intercellular coupling of SGCs and decreases their 
membrane resistance [34],  which results in neuro-
pathic pain.  SGCs also upregulate the production of 
proinflammatory cytokines such as tumor necrosis fac-
tor-α after peripheral nerve injury [35].  Our results 
suggest that quercetin’s inhibition of SGCs,  as demon-
strated by GFAP suppression,  attenuates pain behavior.  
However,  further studies will be needed to elucidate the 
analgesic mechanisms of quercetin subsequent to GFAP 
suppression.
Quercetin is widely retailed and used as a supple-
ment with a wide margin of safety.  In a rodent trial,  
quercetin supplementation at a dose of 3-3,000 mg/day 
for 28 days resulted in no significant variations in stan-
dard toxicological parameters and unremarkable find-
ings in the histopathological examination of various 
organs [36].  The bioavailability of quercetin following 
oral administration greatly influences its potential tox-
icity and beneficial effects.  Our preliminary study 
showed a plasma quercetin concentration of 14.2 ± 5.1  
µM in rats following 1% quercetin oral administration 
for 14 days.  In humans,  quercetin supplementation at 
doses of 500 mg/day and 1,000 mg/day over 12 weeks 
resulted in plasma quercetin concentrations of 
1.38 ± 0.07 µM and 2.0 ± 0.1 µM,  respectively [37].  
Although there is a large divergence between our data 
and the reported plasma concentration in humans,  
quercetin intake may be affected by daily diet and sup-
plementation [38].  Some of the therapeutic effects of 
quercetin,  such as decreasing systolic blood pressure 
and reducing markers of oxidative stress and inflamma-
tion,  have been reported at lower doses [17 , 39].  In 
addition,  in clinical practice,  the daily diet may affect 
the outcome of nerve injury.  Shir et al.  reported that 
dietary soy phytoestrogen included in rat chow sup-
pressed neuropathic pain [40].  In this study we used the 
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MF diet as a basal chow.  Although quercetin glycoside 
has been detected in the MF diet,  the amount is vanish-
ingly small [41].  We chose oral administration instead 
of intraperitoneal or intravenous administration not 
only due to the poor solubility of quercetin in solvents,  
but also because a previous report has shown that oral 
digestion with food increases quercetin bioavailability 
[42].  Accordingly,  a number of approaches to increase 
the uptake and bioavailability of quercetin have been 
examined [38].
No analgesic effect of quercetin was observed in the 
post-dose group.  Given this behavioral observation and 
the results of our western blotting,  SGC activation 
seems to contribute to the initiation of pain processing 
rather than its maintenance.  Many examples from the 
literature describing glial roles in chronic pain develop-
ment suggest that microglia have an initiating role and 
astrocytes a maintaining role [43-44].  However,  previ-
ous reports have mainly focused on these cells in the 
spinal dorsal horn.  Evidence of early activation of SGCs 
after nerve injury has been reported.  GFAP has been 
found to be upregulated within 24 h after axotomy [45] 
and SNI-induced GFAP upregulation to peak on days 3 
to 6,  then decline up to day 10 [16].  In the SNI model,  
pain behavior continues for more than 3 weeks [9].  
Although inflammatory components are involved in the 
early postoperative period,  it is generally accepted that 
neuropathic components are the major cause of contin-
uous pain after 1 week.  Because,  in the present study,  
1% quercetin attenuated pain behavior for 21 days 
compared with the control group,  we can conclude that 
quercetin was effective against neuropathic pain.  Taken 
together,  our results highlight the importance of early 
SGC activation in the development of chronic pain 
states.  Further experiments are needed to investigate 
the detailed mechanism of the signaling,  including the 
role of cytokines and the gap junctions between SGCs 
and the neurons affected by quercetin administration.
In conclusion,  prophylactic quercetin suppressed 
the development of neuropathic pain behavior through 
a mechanism partly involving the inhibition of SGCs.  
As its safety has been well established,  quercetin has 
great potential for clinical use in pain treatment.
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